SANDRA META SWAIN, M.D.
Osteopathic Medicine in Bethesda, MD
License number
Maryland D-29517
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
8901 Wisconsin Ave Bldg 8 ROOM 5101, Bethesda, MD 20889
Phone
(301) 435-5416
(301) 496-0047 (Fax)
(301) 365-9206
(301) 496-0047 (Fax)
(301) 365-9206
Personal information
See more information about SANDRA META SWAIN at radaris.comName
Address
Phone
3714 E Northern Pkwy #1, Baltimore, MD 21206
9520 Eagle Ridge Dr, Bethesda, MD 20817
2511 Burridge Rd, Parkville, MD 21234
9520 Eagle Ridge Dr, Bethesda, MD 20817
Professional information
See more information about SANDRA META SWAIN at trustoria.com
Method Of Selecting Cancer Patients For Anti-Angiogenesis Therapy In Combination With Chemotherapy
Method Of Selecting Cancer Patients For Anti-Angiogenesis Therapy In Combination With Chemotherapy
US Patent:
2014006, Mar 6, 2014
Filed:
Mar 1, 2012
Appl. No.:
14/002455
Inventors:
Sherry X. Yang - Ellicott City MD, US
Sandra M. Swain - Bethesda MD, US
Seth M. Steinberg - North Potomac MD, US
Sandra M. Swain - Bethesda MD, US
Seth M. Steinberg - North Potomac MD, US
Assignee:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVIC - Bethesda MD
International Classification:
G01N 33/574
US Classification:
514 34, 514 49, 514449, 435 792
Abstract:
What is described is a method for identifying a cancer patient that is amenable to anti-angiogenesis therapy in combination with chemotherapy for longer overall survival and/or progression-free survival by measuring the status of tumor cell HER2 expression, p53 expression, and apoptosis or endothelial cell CD31 expression in a tumor sample obtained from the patient prior to treatment. Bevacizumab, an antibody to vascular endothelial growth factor, is a preferred anti-angiogenesis therapy for treating several cancer types including breast cancer. Cancer patients with p53-negative or HER2 negative tumors, especially dual p53 HER2-negative tumors or tumors with low levels of apoptosis or high endothelial cell CD31 expression in the tumor samples are more amenable to anti-angiogenesis therapy with bevacizumab. These tumor characteristics provide a diagnostic method for identifying cancer patients amendable to anti-angiogenesis therapy plus chemotherapy for better treatment outcome.
Akt Phosphorylation At Ser473 As An Indicator For Taxane-Based Chemotherapy
Akt Phosphorylation At Ser473 As An Indicator For Taxane-Based Chemotherapy
US Patent:
2012014, Jun 7, 2012
Filed:
May 21, 2010
Appl. No.:
13/322140
Inventors:
Sherry X. Yang - Ellicott City MD, US
Sandra M. Swain - Bethesda MD, US
Sandra M. Swain - Bethesda MD, US
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Serv - Bethesda MD
International Classification:
A61K 31/337, G01N 21/75, C40B 30/04, A61K 31/704, A61P 35/04, G01N 33/566, A61P 35/00
US Classification:
514 34, 435 71, 514449, 506 9
Abstract:
Methods for determining whether a cancer patient is likely to benefit from treatment with a taxane compound based on Akt-Ser473 phosphorylation status are provided, together with kits for determining Akt-Ser473 phosphorylation status and methods for improving treatment of a cancer patient that include obtaining a determination of the Akt-Ser473 phosphorylation status of the cancer.
Akt Phosphorylation At Ser473 As An Indicator For Taxane-Based Chemotherapy
Akt Phosphorylation At Ser473 As An Indicator For Taxane-Based Chemotherapy
US Patent:
2014001, Jan 9, 2014
Filed:
Sep 19, 2013
Appl. No.:
14/031699
Inventors:
Sherry X. Yang - Ellicott City MD, US
Sandra M. Swain - Bethesda MD, US
Sandra M. Swain - Bethesda MD, US
International Classification:
G01N 33/574
US Classification:
514449, 435 74
Abstract:
Methods for determining whether a cancer patient is likely to benefit from treatment with a taxane compound based on Akt-Ser473 phosphorylation status are provided, together with kits for determining Akt-Ser473 phosphorylation status and methods for improving treatment of a cancer patient that include obtaining a determination of the Akt-Ser473 phosphorylation status of the cancer.